HSP90 inhibitor RGRN‐305 for oral treatment of plaque‐type psoriasis: efficacy, safety and biomarker results in an open‐label proof‐of‐concept study*

Treatment with RGRN-305 showed acceptable safety, especially in the low-dose group, and was associated with clinically meaningful improvement in a subset of patients with plaque psoriasis, indicating that HSP90 may serve as a novel future target in psoriasis treatment.